Oligodendroglioma other imaging findings: Difference between revisions
Jump to navigation
Jump to search
| Line 33: | Line 33: | ||
===Positron Emission Tomography=== | ===Positron Emission Tomography=== | ||
*[[PET|11C-Methionine PET]] and [[PET|F-18 FDG PET]] studies can be used to differentiate oligodendroglioma from anaplastic oligodendroglioma.<ref name=Radio>Radiographic features of oligodendroglioma. Dr. Henry Knipe and Dr. Frank Gaillard et al. http://radiopaedia.org/articles/oligodendroglioma</ref> | *[[PET|11C-Methionine PET]] and [[PET|F-18 FDG PET]] studies can be used to differentiate oligodendroglioma from anaplastic oligodendroglioma.<ref name=Radio>Radiographic features of oligodendroglioma. Dr. Henry Knipe and Dr. Frank Gaillard et al. http://radiopaedia.org/articles/oligodendroglioma</ref> | ||
*[[Florbetapir (18F)|[18F]-fluorodeoxyglucose]] (FDG) uptake of oligodendroglioma is similar to normal [[white matter]], whereas FDG uptake of [[anaplastic|anaplastic oligodendroglioma]] is similar to normal [[gray matter]] | *[[PET|[18F]fluorodeoxyglucose-PET]] scan has been helpful in:<ref name=Radio>Radiographic features of oligodendroglioma. Dr. Henry Knipe and Dr. Frank Gaillard et al. http://radiopaedia.org/articles/oligodendroglioma</ref><ref name="pmid16908552">{{cite journal| author=Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L| title=[11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. | journal=AJNR Am J Neuroradiol | year= 2006 | volume= 27 | issue= 7 | pages= 1432-7 | pmid=16908552 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16908552 }} </ref> | ||
**Differeniating oligodendroglioma from [[anaplastic|anaplastic oligodendroglioma]] - [[Florbetapir (18F)|[18F]-fluorodeoxyglucose]] (FDG) uptake of oligodendroglioma is similar to normal [[white matter]], whereas FDG uptake of [[anaplastic|anaplastic oligodendroglioma]] is similar to normal [[gray matter]] | |||
**Differentiating [[tumor]] recurrence from tumor [[necrosis]] | |||
**Therapy response assessment | |||
===Bone Scan=== | ===Bone Scan=== | ||
Revision as of 23:12, 13 October 2015
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma other imaging findings On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma other imaging findings |
|
Risk calculators and risk factors for Oligodendroglioma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Other Imaging Findings
Other imaging studies for oligodendroglioma include:[1][2][3][4]
Magnetic Resonance Spectroscopy
- N-acetyl aspartate (NAA) peak is dominant
- Choline-to-creatine ratio of less than 3:1
- Reduction of NAA/creatine ratio
- Increased choline levels and decreased NAA levels with a myo-inositol peak
- Increased glutamine and glutamate levels in low-grade oligodendroglioma in contrast to high-grade oligodendroglioma
- Increased lipid and lactate levels in high-grade oligodendroglioma in contrast to low-grade oligodendroglioma
Images
-
![On spectroscopy, the lesion demonstrates increased choline and decreased NAA with a myo-inositol peak.[5]](/images/0/03/MRS_oligodendroglioma.jpeg)
On spectroscopy, the lesion demonstrates increased choline and decreased NAA with a myo-inositol peak.[5]
![On spectroscopy, the lesion demonstrates increased choline and decreased NAA with a myo-inositol peak.[5]](/index.php/File:MRS_oligodendroglioma.jpeg)
Magnetic Resonance Perfusion
- There is increased "chicken wire" network of vascularity, which results in elevated relative cerebral blood volume (rCBV).[6]
- MR perfusion has a sensitivity of 95% for distinguishing grade II from grade III oligodendrogliomas. rCBV above the threshold of 1.75 demonstrates more rapid tumor progression.
Images
-
![MR perfusion demonstrates significantly increased CBV (area 'under' the purple curve) compared to the other side.[7]](/images/7/76/MR_perfusion_oligodendroglioma_1.jpg)
MR perfusion demonstrates significantly increased CBV (area 'under' the purple curve) compared to the other side.[7] -
![MR perfusion of the brain.[7]](/images/0/0c/MR_perfusion_oligodendroglioma_2.jpg)
MR perfusion of the brain.[7]
![MR perfusion demonstrates significantly increased CBV (area 'under' the purple curve) compared to the other side.[7]](/index.php/File:MR_perfusion_oligodendroglioma_1.jpg)
![MR perfusion of the brain.[7]](/index.php/File:MR_perfusion_oligodendroglioma_2.jpg)
Positron Emission Tomography
- 11C-Methionine PET and F-18 FDG PET studies can be used to differentiate oligodendroglioma from anaplastic oligodendroglioma.[6]
- [18F]fluorodeoxyglucose-PET scan has been helpful in:[6][8]
- Differeniating oligodendroglioma from anaplastic oligodendroglioma - [18F]-fluorodeoxyglucose (FDG) uptake of oligodendroglioma is similar to normal white matter, whereas FDG uptake of anaplastic oligodendroglioma is similar to normal gray matter
- Differentiating tumor recurrence from tumor necrosis
- Therapy response assessment
Bone Scan
- Most malignant gliomas get metastasized to the bones via the hematogenous spread.[9]
- Bone scan may be performed to detect metastases of malignant oligodendroglioma or anaplastic oligodendroglioma to bones.[10]
References
- ↑ Eskandar EN, Loeffler JS, O'Neill AM, Hunter GJ, Louis DN (2004). "Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 33-2004. A 34-year-old man with a seizure and a frontal-lobe brain lesion". N Engl J Med. 351 (18): 1875–82. doi:10.1056/NEJMcpc049025. PMID 15509821.
- ↑ Nikaido K, Nihira H, Wakai S, Honmo O, Tsuzuki A (2003). "[A case of oligodendroglioma with temporal lobe epilepsy initially suspected as having paroxymal tachycardia]". No To Hattatsu. 35 (5): 401–5. PMID 13677949.
- ↑ Axial MRS of oligodendroglioma. Dr. Bruno Di Muzio. Radiopaedia 2015. http://radiopaedia.org/cases/oligodendroglioma-14
- ↑ Rijpkema M, Schuuring J, van der Meulen Y, van der Graaf M, Bernsen H, Boerman R; et al. (2003). "Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging". NMR Biomed. 16 (1): 12–8. doi:10.1002/nbm.807. PMID 12577293.
- ↑ Image courtesy of Dr. Bruno Di Muzio. Radiopaedia (original file here). Creative Commons BY-SA-NC
- ↑ 6.0 6.1 6.2 Radiographic features of oligodendroglioma. Dr. Henry Knipe and Dr. Frank Gaillard et al. http://radiopaedia.org/articles/oligodendroglioma
- ↑ 7.0 7.1 Image courtesy of Dr. Frank Gaillard. Radiopaedia (original file here). Creative Commons BY-SA-NC
- ↑ Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L (2006). "[11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence". AJNR Am J Neuroradiol. 27 (7): 1432–7. PMID 16908552.
- ↑ Beauchesne P (2011). "Extra-neural metastases of malignant gliomas: myth or reality?". Cancers (Basel). 3 (1): 461–77. doi:10.3390/cancers3010461. PMC 3756372. PMID 24212625.
- ↑ Al-Ali F, Hendon AJ, Liepman MK, Wisniewski JL, Krinock MJ, Beckman K (2005). "Oligodendroglioma metastatic to bone marrow". AJNR Am J Neuroradiol. 26 (9): 2410–4. PMID 16219856.